March 26, 2020 / 2:16 PM / 9 days ago

BRIEF-Myokardia Says Studies Planned To Initiate In Q2 Will Be Delayed Until Conditions Change

March 26 (Reuters) - MyoKardia Inc:

* MYOKARDIA - REAFFIRMS Q2 EXPECTED TIMING FOR TOPLINE DATA FROM PHASE 3 EXPLORER-HCM CLINICAL TRIAL OF MAVACAMTEN AND PHASE 2A DANICAMTIV STUDY

* MYOKARDIA - HAS TEMPORARILY SUSPENDED ROLLOVER OF PATIENTS FROM EXPLORER INTO THE MAVA-LTE AND PLANS TO RESUME ENROLLMENT WHEN CONDITIONS PERMIT

* MYOKARDIA -HAS ALSO PAUSED ENROLLMENT OF HEALTHY VOLUNTEERS IN PHASE 1 CLINICAL TRIAL EVALUATING MYK-224.

* MYOKARDIA - STUDIES THAT WERE PLANNED TO INITIATE IN Q2 2020 WILL BE DELAYED UNTIL CONDITIONS CHANGE Source: (bit.ly/2UCJBDV) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below